CRISPR Stock Performance

CRSP
 Stock
  

USD 63.70  3.20  4.78%   

On a scale of 0 to 100, CRISPR Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of 1.6509, which signifies a somewhat significant risk relative to the market. Let's try to break down what CRISPR's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CRISPR Therapeutics will likely underperform. Although it is important to respect CRISPR Therapeutics historical returns, it is better to be realistic regarding the information on the equity's current trending patterns. The approach to foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By reviewing CRISPR Therapeutics technical indicators, you can today evaluate if the expected return of 0.22% will be sustainable into the future. Please makes use of CRISPR Therapeutics potential upside, and the relationship between the total risk alpha and kurtosis to make a quick decision on whether CRISPR Therapeutics price patterns will revert.
  
Refresh
CRISPR Performance
3 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady basic indicators, CRISPR Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more

CRISPR Price Channel

Quick Ratio19.54
Fifty Two Week Low42.51
Target High Price220.00
Fifty Two Week High169.76
Target Low Price46.00

CRISPR Therapeutics Relative Risk vs. Return Landscape

If you would invest  6,408  in CRISPR Therapeutics AG on March 30, 2022 and sell it today you would earn a total of  282.00  from holding CRISPR Therapeutics AG or generate 4.4% return on investment over 90 days. CRISPR Therapeutics AG is currently generating 0.2225% in daily expected returns and assumes 5.5339% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than CRISPR, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days CRISPR Therapeutics is expected to generate 3.83 times more return on investment than the market. However, the company is 3.83 times more volatile than its market benchmark. It trades about 0.04 of its potential returns per unit of risk. The DOW is currently generating roughly -0.12 per unit of risk.

CRISPR Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for CRISPR Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CRISPR Therapeutics AG, and traders can use it to determine the average amount a CRISPR Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0402

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsCRSP
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 5.53
  actual daily
 
 47 %
of total potential
 
4747
Expected Return
 0.22
  actual daily
 
 4 %
of total potential
 
44
Risk-Adjusted Return
 0.04
  actual daily
 
 3 %
of total potential
 
33
Based on monthly moving average CRISPR Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CRISPR Therapeutics by adding it to a well-diversified portfolio.

About CRISPR Therapeutics Performance

To evaluate CRISPR Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when CRISPR Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare CRISPR Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand CRISPR Therapeutics stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents CRISPR's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Effect of Exchange Rate Changes on Cash-11 K-11.3 K
Return on Average Assets 0.14  0.16 
Return on Average Equity 0.16  0.17 
Return on Invested Capital 0.26  0.28 
Return on Sales 0.41  0.45 
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

Things to note about CRISPR Therapeutics

Checking the ongoing alerts about CRISPR Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for CRISPR Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

CRISPR Therapeutics Alerts

Equity Alerts and Improvement Suggestions

CRISPR Therapeutics has very high historical volatility over the last 90 days
About 61.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.benzinga.com: Statistics on Global CRISPR Genome Editing Market Size Share to Surpass USD 15.84 Billion by 2028, Exhi - Benzinga
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.